argenx
Focus: Argenx is a European biotechnology company specialized in antibody therapies, with a commercial-stage portfolio focused on autoimmune and rare diseases. As of 2026, it has achieved significant market traction with VYVGART generating substantial revenue and establishing itself as one of Europe's most valuable biotechs.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Open Jobs
88+42 this month
Hot — 73 jobs added in 30d
Net +42 (73 new, 31 removed). Aggressive expansion phase.
Should You Work at argenx?
AI assessmentArgenx is a high-risk, high-reward mid-cap with validated commercial execution on one asset but structural dependence on VYVGART; best for candidates seeking antibody-focused science and near-term milestone exposure, with acceptance of single-product business model risk.
Why Work Here
- Commercial momentum: VYVGART reached peak lifecycle status with $200M in Part D spending, providing visibility into revenue trajectory and commercial execution opportunities.
Data completeness
5/9 — Partial
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$200M Part DGrowing
Peak
Flagship product driving 96% of revenue; demonstrates FcRn inhibition efficacy and has established reimbursement pathway with sustained Part D spending.
Help build intelligence for argenx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.